Skip to content
AnalystLens

Halozyme Therapeutics 8-K Report, Financial Results (Jan 8, 2025)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed January 8, 2025
Period End
January 8, 2025
Security
HALO
In the record · 2016–202610-K1110-Q338-K141

HALO filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 141 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jul ’17Jul ’17
  2. Leadership change8-K · Feb ’20Feb ’20
  3. Material agreement8-K · Aug ’22Aug ’22
  4. Leadership change8-K · Sep ’26Sep ’26

Summary

Summary of the 8-K filed January 8, 2025. Cited figures are marked; the original filing is the authoritative source.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) furnished a press release dated January 8, 2025 under Item 2.02 reiterating its 2024 financial guidance and raising its 2025 and multi-year guidance.

The company's preliminary, unaudited 2024 estimates show total revenue of $970 to $1,020 milliona, royalty revenue of $550 to $565 million, net income of $419 to $443 million, adjusted EBITDA of $595 to $625 million, GAAP diluted EPS of $3.22 to $3.40, and non-GAAP diluted EPS of $4.00 to $4.20. The company notes these estimates are subject to completion of its financial close and could vary materially from final results in its Form 10-K. For 2025, Halozyme raised its guidance ranges: total revenue of $1,150 million to $1,225 million (16% to 23% growth over projected 2024), royalty revenue of $725 million to $750 million (30% to 35% growth), adjusted EBITDA of $755 million to $805 million (24% to 32% growth), and non-GAAP diluted EPS of $4.95 to $5.35 (21% to 30% growth).

Prior 2025 ranges were total revenue of $1,095 million to $1,170 millionb, royalty revenue of $650 million to $675 million, adjusted EBITDA of $710 million to $760 million, and non-GAAP diluted EPS of $4.45 to $4.85. The company attributes the outlook mainly to VYVGART Hytrulo, Darzalex SC and Phesgo, with Ocrevus Zunovo, Tecentriq Hybreza and Opdivo Qvantig expected to contribute modestly in 2025.

The company also announced a new $250 millionc accelerated share repurchase program under its previously announced $750 million share repurchase program. The 2025 EPS guidance does not consider the impact of potential future share repurchases.

Key Highlights

  1. Preliminary 2024 total revenue estimated at $970 to $1,020 million, with royalty revenue of $550 to $565 million; 2024 guidance reiterated.
  2. 2025 total revenue guidance raised to $1,150 to $1,225 million from $1,095 to $1,170 million, representing 16% to 23% growth.
  3. 2025 royalty revenue guidance raised to $725 to $750 million from $650 to $675 million, representing 30% to 35% growth.
  4. 2025 adjusted EBITDA guidance raised to $755 to $805 million from $710 to $760 million; non-GAAP diluted EPS guidance raised to $4.95 to $5.35 from $4.45 to $4.85.
  5. Preliminary 2024 GAAP net income estimated at $419 to $443 million and GAAP diluted EPS at $3.22 to $3.40.
  6. Company announced a new $250 million accelerated share repurchase under its previously announced $750 million program.
  7. Multi-year financial guidance was also raised, driven by continued growth across the ENHANZE co-formulated product portfolio.

Frequently Asked Questions

  1. Why did Halozyme raise its 2025 guidance?

    The company attributes the raised outlook mainly to VYVGART Hytrulo, which has received strong early acceptance in generalized myasthenia gravis and is seeing growing adoption in CIDP following its June 2024 U.S. approval, as well as continued strong growth of Darzalex SC and Phesgo.

  2. What are the 2025 guidance ranges?

    Total revenue of $1,150 million to $1,225 million, royalty revenue of $725 million to $750 million, adjusted EBITDA of $755 million to $805 million, and non-GAAP diluted EPS of $4.95 to $5.35.

  3. Are the 2024 preliminary results final?

    No. The 2024 figures are preliminary, estimated and unaudited, remain subject to the completion of financial and accounting close procedures, and could vary materially from the results reported in the Form 10-K for the year ended December 31, 2024.

  4. Does the 2025 EPS guidance include future buybacks?

    No. The company states its earnings per share guidance does not consider the impact of potential future share repurchases.

  5. What is the new share repurchase program?

    Halozyme entered into a new $250 million accelerated share repurchase (ASR) program under its previously announced $750 million share repurchase program.